89Zr-Df-crefmirlimab

锆（89Zr）贝可瑞利单抗

Report date: 2025/09/10 20:01:13

Base Information

Drug Name89Zr-Df-crefmirlimab
Drug Alias Name（89Zr）贝可瑞利单抗CD8 T Cell imaging agent89Zr-贝可瑞利单抗Minibody CD8 T Cell imaging agentCD8-ImmunoPET +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > ImmunoglobulinDiagnostic agent (In vivo) +[8] 
Mechanisms of ActionPositron-emission tomography enhancersCluster of differentiation 8 modulators
TargetsCluster of differentiation 8
Therapy Area/IndicationsSkin MelanomaSolid tumoursMultiple Sclerosis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesImaginab Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenDynamiCure Biotechnology LtdPfizer Inc +[7] 
Inactive CompaniesN/A
Active IndicationsSkin MelanomaSolid tumoursMultiple Sclerosis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A